Neurological aspects of COVID-19

Cover Page

Cite item

Full Text


Research Center of Neurology, Moscow, Russia

The novel coronavirus pandemic presents one of the most significant challenges to modern healthcare, which involves all medical specialties. The current review encompasses the neurologic manifestations of COVID-19 — a yet to be defined problem. L. Mao et al. have found a third of COVID-19 patients to exhibit neurological symptoms the latter divided into three categories: central nervous system involvement (vertigo, headache, altered consciousness, acute cerebrovascular pathology, ataxia, and seizures) in 24.8% of patients, peripheral nervous system involvement (smell and taste disorders, neuropathy) — 8.9%, and muscle pathology (muscle pain, associated with creatine kinase increase) — 10,7%. Cerebrovascular pathology in 221 patients, described by Y. Li et al. occurred in 5.9% of cases — the majority was comprised by ischemic stroke, and as a whole it was associated with a more severe disease course. T. Oxley et al. described 5 patients (less than 50 years of age) with a large-vessel stroke occurring as a result of COVID-19. It has been shown that meningoencephalitis may be linked to COVID-19 — this review addresses several described cases. A case series of Guillain-Barre syndrome n patients with SARAS-CoV-2 infection is also described. Apart from that, it is well established that SARS-CoV-2 may lead to deterioration of concurrent somatic and (or) neurological diseases, worsening the prognosis.

About the authors

Marine M. Tanashyan

Research Center of Neurology

Russian Federation, Moscow

Polina I. Kuznetsova

Research Center of Neurology

Russian Federation, Moscow

Anton A. Raskurazhev

Research Center of Neurology

Author for correspondence.
Russian Federation, Moscow


  1. Corman V.M., Muth D., Niemeyer D., Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res 2018, 100: 163–188. doi: 10.1016/bs.aivir.2018.01.001. PMID: 29551135.
  2. Matías-Guiu J., Gomez-Pinedo U., Montero-Escribano P. et al. Should we expect neurological symptoms in the SARS-CoV-2 epidemic? Neurologia 2020; 35: 170–175. doi: 10.1016/j.nrleng.2020.03.002. PMID: 32299636.
  3. Li Q., Guan X., Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. N Engl J Med 2020; 382: 1199–1207. doi: 10.1056/nejmoa2001316. PMID: 31995857.
  4. Goyal P., Choi J.J., Pinheiro L.C. et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020. doi: 10.1056/nejmc2010419. PMID: 32302078.
  5. Mao L., Jin H., Wang M. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020. doi: 10.1001/jamaneurol.2020.1127. PMID: 32275288.
  6. Miwa T., Ikeda K., Ishibashi T. et al. Clinical practice guidelines for the management of olfactory dysfunction — secondary publication. Auris Nasus Larynx 2019; 46: 653–662. doi: 10.1016/j.anl.2019.04.002. PMID: 31076272.
  7. Helms J., Kremer S., Merdji H. et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020. doi: 10.1056/nejmc2008597. PMID: 32294339.
  8. Bikdeli B., Madhavan M.V., Jimenez D. et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol 2020. doi: 10.1016/j.jacc.2020.04.031. PMID: 32311448.
  9. Klok F.A., Kruip M.J.H.A., van der Meer N.J.M. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020. doi: 10.1016/j.thromres.2020.04.013. PMID: 32291094.
  10. Li Y. et al. Acute cerebrovascular disease following COVID-19: A single center, retrospective, observational study. SSRN Electron J 2020. doi: 10.2139/ssrn.3550025.
  11. Avula A., Nalleballe K., Narula N. et al. COVID-19 presenting as stroke. Brain Behav Immun 2020. doi: 10.1016/j.bbi.2020.04.077. PMID: 32360439.
  12. Oxley T.J., Mocco J., Majidi S. et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 2020. doi: 10.1056/nejmc2009787. PMID: 32343504.
  13. Asadi-Pooya A.A., Simani L. Central nervous system manifestations of COVID-19: A systematic review. J Neurol Sci 2020; 413: 116832. doi: 10.1016/j.jns.2020.116832. PMID: 32299017.
  14. Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. doi: 10.1016/s0140-6736(20)30183-5. PMID: 31986264.
  15. Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020. doi: 10.1016/s2213-2600(20)30079-5. PMID: 32105632.
  16. Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020; 323: 1061–1069. doi: 10.1001/jama.2020.1585. PMID: 32031570.
  17. Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507–513. doi: 10.1016/s0140-6736(20)30211-7. PMID: 32007143.
  18. Desforges M., Le Coupanec A., Stodola J.K. et al. Human coronaviruses: viral and cellular factors involved in neuroinvasiveness and neuropathogenesis. Virus Res 2014; 194: 145–158. doi: 10.1016/j.virusres.2014.09.011. PMID: 25281913.
  19. Gu J., Gong E., Zhang B. et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med 2005; 202: 415–424. doi: 10.1084/jem.20050828. PMID: 16043521.
  20. Dubé M., Le Coupanec A., Wong A.H.M. et al. Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43. J Virol 2018; 92: e00404–e00418. doi: 10.1128/jvi.00404-18. PMID: 29925652.
  21. Conde Cardona G., Quintana Pájaro L.D., Quintero Marzola I.D. et al. Neurotropism of SARS-CoV 2: mechanisms and manifestations. J Neurol Sci 2020; 412: 116824. doi: 10.1016/j.jns.2020.116824. PMID: 32299010.
  22. Wu Y., Xu X., Chen Z. et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020. doi: 10.1016/j.bbi.2020.03.031. PMID: 32240762.
  23. Zhou L., Zhang M., Wang J., Gao J. Sars-Cov-2: underestimated damage to nervous system. Travel Med Infect Dis 2020: 101642. doi: 10.1016/j.tmaid.2020.101642. PMID: 32220634.
  24. Poyiadji N., Shahin G., Noujaim D. et al. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. Radiology 2020: 201187. doi: 10.1148/radiol.2020201187. PMID: 32228363.
  25. Kim J.E., Heo J.H., Kim H.O. et al. Neurological complications during treatment of Middle East Respiratory Syndrome. J Clin Neurol 2017; 13: 227–233. doi: 10.3988/jcn.2017.13.3.227. PMID: 28748673.
  26. Camdessanche J. P., Morel J., Pozzetto B. et al. COVID-19 may induce Guillain–Barré syndrome. Rev Neurol (Paris) 2020. doi: 10.1016/j.neurol.2020.04.003. PMID: 32334841.

Supplementary files

Supplementary Files

Copyright (c) 2020 Tanashyan M.M., Kuznetsova P.I., Raskurazhev A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies